Inhibitors of epidermal growth factor receptor (EGFR), including low molecular weight inhibitor erlotinib and gefitinib, have been demonstrated to be active antitumor agents in patients with non-small cell lung carcinoma and head and neck carcinomas. Increased concentrations of urinary neopterin, an indicator of systemic immune activation, have also been reported in patients with lung carcinoma and head and neck carcinomas. EGFR blockade has been reported to induce immune activation. We have measured, using high performance liquid chromatography, urinary neopterin in patients with non-small cell lung carcinoma and head and neck carcinomas treated with gefitinib. Intestinal permeability was also investigated at baseline by measuring, using capillary gas chromatography, urinary xylose, mannitol and lactulose after oral challenge. Compared to controls, urinary neopterin was significantly increased in patients with non-small cell lung carcinoma. No significant change in urinary neopterin was observed during the therapy with gefitinib. A significant correlation was observed between urinary neopterin and xylose absorption (r s = -0.58, p <0.05), lactulose/mannitol (r s = 0.75, p <0.01), and lactulose/xylose (r s = 0.62, p <0.05) ratios. In conclusion, EGFR blockade had no effect on systemic immune activation, evaluated with urinary neopterin. A significant correlation has been observed between urinary neopterin and parameters of intestinal permeability and absorption.
Introduction
Epidermal growth factor receptor (EGFR) plays an important role in tumor progression, and strategies aimed at inhibition of EGFR signaling have recently been introduced into the therapy of solid tumors. Anti-EGFR agents include monoclonal antibodies and lowmolecular inhibitors, e.g. gefitinib. Encouraging data have been originally reported for gefitinib in the therapy of non-small cell lung carcinoma (1, 2) and head and neck carcinomas (3) . The therapy with EGFR inhibitors is generally well tolerated, but, similarly to other biological agents, EGFR inhibitors are associated with a peculiar toxicity profile, notably skin rash. The toxic effects of EGFR blockade reflect the multiple physiological roles of the receptor and its endogenous ligands. However, the information about the effect of EGFR blockade on systemic immune activation is limited. An enhanced immune response has been reported to result from EGFR blockade (4, 5) .
Urinary and serum concentrations of neopterin, an indicator of systemic immune activation, are increased in patients with advanced tumors, including lung cancer and head and neck carcinomas (6) (7) (8) . Increased neopterin is a prognostic factor associated with inferior survival. Moreover, changes in neopterin concentrations have been observed in body fluids of cancer patients treated with cytokines or cytotoxic agents (9, 10) . Measurement of intestinal permeability is used to study the disorders of the barrier function of the gut mucosa in benign disorders, including inflammatory bowel disease and gluten enteropathy. The disorders of this barrier function may be defined by altered permeability to different substances, including non-metabolizable sugars. Intestinal permeability was also tested in patients treated by cytotoxic agents, and aberrations similar to those found in patients with benign intestinal disorders have been described (11) .
In the present study, we have assessed urinary neopterin during the therapy with gefitinib in patients with lung cancer and head and neck carcinomas. We have observed no effect of gefitinib administration on urinary neopterin concentrations. In addition, intestinal permeability and xylose absorption were investigated in the patients at baseline, and a correlation has been observed between urinary neopterin and parameters of intestinal permeability and absorption.
Patients and Methods
Sixteen patients, aged (mean ± standard deviation) 56 ± 9, range 39 -71 years enrolled in an expanded access program of gefitinib (Iressa, AstraZeneca, Macclesfield, United Kingdom) were studied. Ten patients, 8 males and 2 females, had non-small cell lung carcinoma and 6 patients, all males, had head and neck carcinoma. Nineteen healthy subjects, aged 52 ± 15, range 25 -88 years, 10 males and 9 females served as control group. All subjects studied were Caucasians. All patients have received prior chemotherapy and/or radiotherapy. Gefitinib was administered daily at the dose of 250 mg (in patients with non-small cell lung carcinoma) or 500 mg (in patients with head and neck carcinomas).
Urine sample were collected at scheduled visits, and stored at -20°C until analysis. After centrifugation (5 minutes, 1300 g) and diluting 100 µl of urine specimens with 1.0 ml of mobile phase containing 2 g of disodium-EDTA per liter, samples were injected onto a column, and neopterin was determined using high performance liquid chromatography systems LC1084A with HP 79850 A integrator (Hewlett-Packard, Palo Alto, CA, USA) as described (12) . Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission) and quantified by external standard method. Creatinine was determined by Jaffé reaction after dilution of the sample 1:50 on a Hitachi 716 analyser (Tokyo, Japan) using a commercial kit (Boehringer, Mannheim, Germany) according to the manufacturer's instructions, and neopterin concentrations were expressed as neopterin to creatinine ratio (µmol/mol creatinine).
Intestinal permeability was investigated by determining urinary lactulose, xylose and mannitol after oral challenge as described earlier (13) . Briefly, after an overnight fast, a pretest urine sample was collected to detect any endogenous mannitol, and the patients ingested 100 ml of the test solution containing 2 g of mannitol, 2 g of xylose, 10 g of lactulose, and 11 g of glucose in water. The patients then continued fasting for 2 hours, and urine was collected for 5 hours. Lactulose, xylose and mannitol were determined by capillary gas chromatography as described (13) Urinary neopterin concentrations of patients and controls were compared by Mann-Whitney U test, and neopterin before and during the treatment was compared by Wilcoxon signed rank test. Correlations were examined by the Spearman's rank correlation coefficient. The decision on statistical significance was based on p = 0.05 level. The analyses were performed using NCSS 2001 software (Number Cruncher Statistical Systems, Kaysville, Utah, USA).
Results
Compared to controls, initial neopterin concentrations were significantly increased in 10 patients with non-small cell lung carcinoma (mean ± standard deviation: 348 ± 348, range: 81 -1265 vs. 151 ± 82, 55-364 µmol/mol creatinine; p <0.05), but not in 6 patients with head and neck carcinomas (171 ± 111, 71-383 µmol/mol creatinine).
Urinary neopterin was evaluated during the course of gefitinib therapy in 16 patients. In 13 patients, samples were obtained immediately before the start of therapy as well as during subsequent visits, while in 3 patients monitoring of urinary neopterin was initiated after the start of treatment. In 13 patients evaluated before the start of therapy, a median number of 6 (range: 2-11) additional measurements were available.
No significant changes were observed in urinary neopterin concentrations during the course of gefitinib therapy when evaluated at 6 subsequent visits at intervals (median) of 15, 34, 59, 80, 99 and 138 days (Figure 1) . Similarly, no significant difference was observed when the pretreatment neopterin and a mean of subsequent neopterin concentrations in each patient were compared (297 ± 319, 71-1265 vs. 250 ± 186, 65-763 µmol/mol creatinine). In most patients, only mild fluctuations were observed during the course of gefitinib therapy. Occasionally, increased urinary neopterin accompanied skin complications or disease progression (Figure 2) .
Intestinal permeability was examined in all 13 patients studied before therapy and in 10 controls. Compared to controls, patients had significantly increased absorption of xylose (26.3 ± 14.3, 6.2-58.6 vs. 13.8 ± 5.2, 7.8-25.5 %), lactulose 0.80 ± 0.87, 0.16-3.62 vs. 0.32 ± 0.15, 0.14-0.53 %), and lactulose/mannitol ratio (0.05 ± 0.04, range 0.02-0.14 vs. 0.02 ± 0.01, 0.01-0.04), while mannitol absorption (18.9 ± 10.5, range 3.9-38.6 vs. 18.2 ± 4.1, 12.6-26.3 %) and lactulose/xylose ratio (0.03 ± 0.04, range 0.01-0.15 vs. 0.02 ± 0.01, 0.01-0.04) were not significantly different in patients and controls. A significant correlation was observed in the patients between urinary neopterin and xylose absorption (r s = -0.58, p <0.05), lactulose/man- 
Discussion
In the present study EGFR blockade had no effect on systemic immune activation. We originally hypothesized that EGFR blockade could induce systemic immune activation through different potential mechanisms. EGFR inhibition could interfere with the barrier function of skin and mucous membranes, leading to increased penetration of microorganisms and systemic immune response. Apoptosis of tumor cells may also induce inflammatory response. In an experimental study, EGFR blockade was associated with an enhanced inflammatory response (4) . An increase in soluble P-selectin, RANTES and soluble interleukin-2 receptor was observed after administration of gefitinib, suggesting that gefitinib may activate cell-mediated immunity (5) . On the other hand, no changes in systemic concentrations of vascular endothelial growth factor or basic fibroblast growth factor were observed after gefitinib therapy (14) .
The hypothesis that gefitinib administration would result in systemic immune activation, was not reflected in an increase neopterin concentrations in the present study. This could be partly due to limited effectiveness of gefitinib as anticancer agent. In fact, original encouraging data with this drug (1, 2) were not confirmed by subsequent studies, and the drug is currently no longer available in the United States and European Union (15) . Gefitinib seems to be more effective in Asian populations, and immune activation induced by the treatment with this drug has been reported in Asian patients (5) . An increase of neopterin production has been documented in cancer patients after systemic administration of different cytokines (9) or with the combination of paclitaxel and doxorubicin (10) . On the other hand, reduction of the tumor burden may result in lower neopterin (16) . Inhibition of tumor growth by gefitinib might result in lower neopterin in some patients with increased baseline neopterin concentrations, and this decrease might neutralize any increase induced by activation of monocytes/macrophages by EGFR blockade.
Urinary neopterin was used here to study systemic immune activation after EGFR blockade. Neopterin is produced from guanosine triphosphate by macrophages stimulated by interferon-γ, and measurement of neopterin concentrations may be used to assess macrophage activation and systemic immune activation (17) . An important advantage of utilization of neopterin for monitoring of systemic immune activation is that neopterin can be measured in urine. Monitoring of urinary neopterin concentrations has already been proven useful in other clinical situation, notably in early detection of transplant rejection (17) . Increased urinary neopterin may also be associated with higher risk of the toxicity of chemotherapy (18, 19) .
In the present study, a significant correlation was observed between urinary neopterin and alterations of Correlation between urinary neopterin and lactulose/mannitol ratio. Shown is the correlation between urinary neopterin and lactulose/mannitol (LAMA) ratio in patients evaluated before the start of gefitinib therapy (r s = 0.75, p = 0.008, n = 11). Lactulose/mannitol ratio was not evaluable in 2 patients because of high background mannitol excretion.
both intestinal permeability (lactulose/mannitol ratio) and absorption (xylose absorption). This observation is similar to the results obtained in a recent study in patients with epithelial ovarian carcinoma (19) . Similarly to earlier reports (20, 21) , present data demonstrate that laboratory parameters of intestinal permeability are increased in cancer patient before the start of therapy. The term intestinal permeability reflects the barrier function of bowel mucosa separating the internal milieu from the outside environment both in an immunologic and a metabolic sense (22) . It has been demonstrated in experimental studies that interferon-γ is responsible for increased intestinal permeability (23, 24) , but clinical data demonstrating an association between systemic immune activation and increased intestinal permeability are limited (19, 25) . Lung cancer is one of the most frequent malignant neoplasms and also one of the most frequent causes of cancer death. Similarly to other tumors, increased neopterin production is associated with poor prognosis. Kronberger et al. (7) assessed the prognostic significance of urinary neopterin in 72 patients with lung cancer. No difference was observed in urinary neopterin according the stage, histology, grade or performance status. Urinary neopterin exhibited a statistically significant positive correlation with leukocytes and serum alkaline phosphatase, and an inverse correlation with hemoglobin concentration. Neopterin was a significant prognostic indicator both in univariate and multivariate analyses. Prommegger et al. (6) evaluated the prognostic significance of urinary neopterin in 110 patients with operable lung carcinoma. Increased urinary neopterin was observed in 20 % of the patients. For 103 patients with non-small cell lung carcinoma, urinary neopterin above 212 µmol/mol creatinine was associated with increased risk of early death. Urinary neopterin and T stage were independent prognostic parameters of survival in the multivariate analysis. Murr et al. (8) investigated urinary neopterin in 23 patients with untreated squamous-cell carcinoma of the oral cavity and in 12 patients with recurrent disease. Increased urinary neopterin was observed in 19 patients, including 9 patients (75 %) with recurrent disease. Urinary neopterin was predictive of survival both in the univariate and in the multivariate analysis.
In conclusion, EGFR blockade had no effect on systemic immune activation, evaluated with urinary neopterin, in Caucasian population. A significant correlation has been observed between urinary neopterin and parameters of intestinal permeability and absorption.
